2. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

ERK Inhibitor

" in MedChemExpress (MCE) Product Catalog:

864

Inhibitors & Agonists

2

Screening Libraries

8

Fluorescent Dyes

8

Biochemical Assay Reagents

37

Peptides

8

Inhibitory Antibodies

201

Natural
Products

46

Isotope-Labeled Compounds

5

Click Chemistry

4

Oligonucleotides

6

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50846
    SCH772984
    180+ Cited Publications

    		 ERK Cancer
    SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations .
    SCH772984
  • HY-15816
    Ulixertinib
    45+ Cited Publications

    BVD-523; VRT752271

    		 ERK Cancer
    Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
    Ulixertinib
  • HY-50706
    Selumetinib
    85+ Cited Publications

    AZD6244; ARRY-142886

    		 MEK Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. Selumetinib can penetrate the blood brain barrier (BBB) .
    Selumetinib
  • HY-15947
    Ravoxertinib
    50+ Cited Publications

    GDC-0994

    		 ERK Cancer
    Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
    Ravoxertinib
  • HY-156002
    LUNA18

    Paluratide

    		 Ras ERK Cancer
    LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .
    LUNA18
  • HY-136579
    ASN007
    5 Publications Verification

    ERK-IN-3

    		 ERK Cancer
    ASN007 (ERK-IN-3) is a potent and orally active inhibitor of ERK. ASN007 inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 exhibits significant anti proliferative activity against various tumor cells. ASN007 can be used for the research of cancers driven by RAS mutations .
    ASN007
  • HY-15816A
    Ulixertinib hydrochloride
    45+ Cited Publications

    BVD-523 hydrochloride; VRT752271 hydrochloride

    		 ERK Cancer
    Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
    Ulixertinib hydrochloride
  • HY-12275
    FR 180204
    20+ Cited Publications

    		 Flavivirus Dengue Virus ERK Apoptosis Cancer
    FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively .
    FR 180204
  • HY-111407
    MK-8353
    5 Publications Verification

    SCH900353

    		 ERK Cancer
    MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.
    MK-8353
  • HY-148510
    HKB99

    		Phosphatase Apoptosis Akt ERK Reactive Oxygen Species (ROS) Cancer
    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 induces apoptosis. HKB99 inhibits the formation of invasive pseudopodia and inhibits migration. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .
    HKB99
  • HY-126288
    ASTX029
    5+ Cited Publications

    		 ERK Apoptosis Cancer
    ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC50: 2.7 nM). ASTX029 has anti-cancer activity .
    ASTX029
  • HY-112287
    ERK1/2 inhibitor 1
    5+ Cited Publications

    		 ERK Cancer
    ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively .
    ERK1/2 inhibitor 1
  • HY-128341
    ERK5-IN-2

    		ERK Cardiovascular Disease Cancer
    ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis .
    ERK5-IN-2
  • HY-18932
    DEL-22379
    2 Publications Verification

    		 ERK Apoptosis Cancer
    DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a Kd estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC50 of ~0.5 μM.
    DEL-22379
  • HY-108330
    AG126
    3 Publications Verification

    Tyrphostin AG126

    		 ERK Mitosis Inflammation/Immunology
    AG126 is a tyrosine kinase inhibitor, can inhibit the phosphorylation of ERK1 and ERK2 at 25-50 μM. AG126 can be used in meiosis, mitosis, and postmitotic research .
    AG126
  • HY-108886
    JWG-071
    5 Publications Verification

    		 ERK Cancer
    JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC50 values of 88nM and 109 nM, respectively .
    JWG-071
  • HY-107753
    XRP44X

    		Ras Inflammation/Immunology Cancer
    XRP44X inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2 . XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules .
    XRP44X
  • HY-14403
    ERK5-IN-1

    		ERK Cancer
    ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
    ERK5-IN-1
  • HY-N0590
    Corynoxeine
    5+ Cited Publications

    		 ERK Cardiovascular Disease
    Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
    Corynoxeine
  • HY-15665
    XMD17-109
    5+ Cited Publications

    		 ERK Cancer
    XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM.
    XMD17-109
  • HY-N1374
    Magnolin
    2 Publications Verification

    		 ERK Inflammation/Immunology
    Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC50s of 87 nM and 16.5 nM, respectively.
    Magnolin
  • HY-112181
    KO-947
    4 Publications Verification

    		 ERK Cancer
    KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.
    KO-947
  • HY-N2283
    Deltonin
    1 Publications Verification

    		 ERK Akt Endogenous Metabolite Cancer
    Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, has antitumor activity; Deltonin inhibits ERK1/2 and AKT activation.
    Deltonin
  • HY-16642A
    LY2828360
    1 Publications Verification

    		 Cannabinoid Receptor Neurological Disease
    LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.
    LY2828360
  • HY-122246
    ML192

    		GPR55 PKC ERK Arrestin Metabolic Disease
    ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβII translocation .
    ML192
  • HY-19820A
    NSC45586 sodium
    1 Publications Verification

    		 Akt Ser/Thr Protease Apoptosis MMP Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .
    NSC45586 sodium
  • HY-112570
    CC-90003
    1 Publications Verification

    		 ERK Cancer
    CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
    CC-90003
  • HY-15947A
    Ravoxertinib hydrochloride
    50+ Cited Publications

    GDC-0994 hydrochloride

    		 ERK Cancer
    Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
    Ravoxertinib hydrochloride
  • HY-150687
    ZINC12409120

    		ERK Metabolic Disease
    ZINC12409120 is a high selective ERK inhibitor. ZINC12409120 acts on disrupting FGF23:α-Klotho interaction to inhibit ERK activity with an IC50 of 5.0 μM .
    ZINC12409120
  • HY-107620
    PD 198306

    		MEK Neurological Disease
    PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .
    PD 198306
  • HY-101846
    AX-15836
    5+ Cited Publications

    		 ERK Inflammation/Immunology Cancer
    AX-15836 is a potent and selective ERK5 inhibitor with an IC50 of 8 nM.
    AX-15836
  • HY-153738
    ERK1/2 inhibitor 9

    		ERK Cancer
    ERK1/2 inhibitor 9 (Probe 1) is a covalent ERK1/2 inhibitor. ERK1/2 inhibitor 9 shows sub-micromolar activity in cells (A375 GI50=0.47 μM). ERK1/2 inhibitor 9 causes the downregulation of phospho-ERK1/2. ERK1/2 inhibitor 9 tagged trans-cyclo-octene (TCO) and Tz-Thalidomide (tetrazine tagged Thalidomide) can form the corresponding ERK-CLIPTAC to elicit degradation of ERK1/2 .
    ERK1/2 inhibitor 9
  • HY-135906
    CK2/ERK8-IN-1
    2 Publications Verification

    		 Casein Kinase ERK Pim DYRK Apoptosis Cancer
    CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 µM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 μM. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy .
    CK2/ERK8-IN-1
  • HY-124740
    ML00253764

    		Melanocortin Receptor Cancer
    ML00253764 is a selective melanocortin receptor 4 (MC4R) antagonist, can induce apoptosis by inhibiting ERK1/2 and Akt phosphorylation, and has anticancer activity .
    ML00253764
  • HY-W001174
    2,5-Dihydroxyacetophenone

    		ERK NF-κB Inflammation/Immunology
    2,5-Dihydroxyacetophenone, isolated from Rehmannia glutinosa, inhibits the production of inflammatory mediators in activated macrophages by blocking the ERK1/2 and NF-κB signaling pathways .
    2,5-Dihydroxyacetophenone
  • HY-121280
    ERK2-IN-4

    		ERK Cancer
    ERK2-IN-4 (Compound 6o) is an effective and selective ERK2 inhibitor with a Ki of 0.006 μM. ERK2-IN-4 inhibits the ERK signaling pathway and can be used in cancer research .
    ERK2-IN-4
  • HY-136579A
    ASN007 benzenesulfonate
    5 Publications Verification

    ERK-IN-3 benzenesulfonate

    		 ERK Cancer
    ASN007 (ERK-IN-3) benzenesulfonate is a potent and orally active inhibitor of ERK. ASN007 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ASN007 benzenesulfonate exhibits significant anti proliferative activity against various tumor cells. ASN007 benzenesulfonate can be used for the research of cancers driven by RAS mutations .
    ASN007 benzenesulfonate
  • HY-15816R
    Ulixertinib (Standard)

    BVD-523 (Standard); VRT752271 (Standard)

    		 ERK Reference Standards Cancer
    Ulixertinib (Standard) is the analytical standard of Ulixertinib. This product is intended for research and analytical applications. Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
    Ulixertinib (Standard)
  • HY-151367
    SHR2415

    		ERK Cancer
    SHR2415 is a highly potent, selective and orally active ERK1/2 inhibitor. SHR2415 has inhibition activity for ERK1 and ERK2 with IC50 values of 2.8 nM and 5.9 nM, respectively. SHR2415 exhibits high potency with an IC50 value of 44.6 nM in Colo205 cells. SHR2415 can be used for the research of cancer .
    SHR2415
  • HY-153445
    Polfurmetinib
    1 Publications Verification

    MEK-IN-6

    		 ERK MEK Cancer
    Polfurmetinib (MEK-IN-6) (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC50: 2 nM). Polfurmetinib can be used for research of cancer .
    Polfurmetinib
  • HY-142433
    ERK1/2 inhibitor 7

    		ERK Cancer
    ERK1/2 inhibitor 7 is a potent ERK inhibitor with an IC50 of 0.94 nM for ERK2 (WO2021110168A1, WX006) .
    ERK1/2 inhibitor 7
  • HY-149414
    MY-673

    		Microtubule/Tubulin Apoptosis ERK TGF-beta/Smad Cancer
    MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization. MY-673 inhibits the ERK signaling pathway, which in turn affects SMAD4 protein expression levels in the TGF-β/SMAD pathway. MY-673 inhibited cell proliferation, migration and induced apoptosis in vivo and in vitro .
    MY-673
  • HY-113592
    ERK-IN-4
    1 Publications Verification

    		 ERK Cancer
    ERK-IN-4 is an ERK inhibitor binds preferentially to ERK2 with a Kd of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 .
    ERK-IN-4
  • HY-107417
    Hypothemycin

    		VEGFR MEK FLT3 PDGFR ERK Cancer
    Hypothemycin, a fungal polyketide, is a multikinase inhibitor with Kis of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2, respectively .
    Hypothemycin
  • HY-145025
    ERK1/2 inhibitor 3

    		ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-162863
    ERK-MYD88 interaction inhibitor 1

    		Apoptosis Cancer
    ERK-MYD88 interaction inhibitor 1 is an ERK-MYD88 interaction inhibitor. ERK-MYD88 interaction inhibitor 1 can induce an HRI-mediated integrated stress response (ISR), leading to cancer cell-specific immunogenic cell apoptosis (apoptosis). ERK-MYD88 interaction inhibitor 1 can induce anti-tumor T cell responses in Lewis lung cancer mice, exhibiting anti-tumor activity .
    ERK-MYD88 interaction inhibitor 1
  • HY-156450
    ERK5-IN-5

    		ERK Cancer
    ERK5-IN-5 (compound 4a) is an ERK5 kinase inhibitor with anticancer activity. ERK5-IN-5 exhibits good anti-proliferative activity with the IC50 value of 6.23 µg/mL for A549 cells .
    ERK5-IN-5
  • HY-161462
    ERK2/p38α MAPK-IN-1

    		ERK p38 MAPK Cancer
    ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC50 of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .
    ERK2/p38α MAPK-IN-1
  • HY-177132
    Sonvuterkib

    WX001

    		 ERK Cancer
    Sonvuterkib (WX001) is a potent and orally active extracellular signal-regulated kinases (ERK) inhibitor with IC50 values of 1.4, 0.54 nM for ERK1, ERK2, respectively. Sonvuterkib inhibits cell proliferation. Sonvuterkib shows anticancer activity .
    Sonvuterkib
  • HY-161363
    ERK2 allosteric-IN-1

    		ERK Metabolic Disease Cancer
    ERK2 allosteric-IN-1 (compound 1) is a selective and allosteric ERK2 inhibitor with the IC50 of 11 μM .
    ERK2 allosteric-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: